Quest will also have early access to Thermo Fisher's pipeline of novel platforms and assays to assist with development of Oncomine-branded solutions.
The partnership includes biopharmaceutical, life science, and non-profit organizations, as well as several US government agencies.
Under the agreement, new companion diagnostics will be included in updates to FoundationOne CDx, which was recently FDA approved.
The LITMUS project will bring together clinicians and researchers from academia and pharma to develop, validate, and quantify better biomarkers for testing NAFLD.
The approved Ventana ALK (D5F3) immunohistochemistry CDx is available for use on the Roche BenchMark XT or BenchMark Ultra IHC/ISH slide staining systems.
The test, developed with Pfizer, could identify renal cancer patients who would experience recurrence, but not who would benefit from adjuvant Sutent.
The initial FDA approval of Thermo Fisher's NGS panel test for personalizing cancer treatment may allow rapid expansion to new indications.
The so-called universal CDx approved by the FDA can gauge alterations across multiple genes associated with response to three lung cancer treatments.
Collaborators have created an atlas that compares available PD-L1 IHC assays and reveals areas of debate, including challenges encountered by clinicians.
The company has also announced a collaboration with Pfizer to develop a blood-based assay to identify critical-stage cardiometabolic conditions.